Limits...
Increased APOBEC3B Predicts Worse Outcomes in Lung Cancer: A Comprehensive Retrospective Study.

Yan S, He F, Gao B, Wu H, Li M, Huang L, Liang J, Wu Q, Li Y - J Cancer (2016)

Bottom Line: Lung cancer ranks as the most common and lethal malignancy in America and worldwide.APOBEC3B is a newly identified DNA cytosine deaminase, which is supposed to function as a major source of DNA mutation in many different tumors.Further research is warranted.

View Article: PubMed Central - PubMed

Affiliation: 1. State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, P.R. China;; 2. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, P.R. China;

ABSTRACT
Lung cancer ranks as the most common and lethal malignancy in America and worldwide. APOBEC3B is a newly identified DNA cytosine deaminase, which is supposed to function as a major source of DNA mutation in many different tumors. In this study, we combine the data of online databases and two hundred and twenty-one primary non-small-cell lung carcinoma (NSCLC) specimens from Sun Yat-sen University Cancer Center to investigate, for the first time, the clinical role of APOBEC3B in lung cancer. We found that the APOBEC3 expression was commonly elevated in NSCLC tissues and overexpression of APOBEC3B was correlated with unfavorable prognosis of the patients with NSCLC. Furthermore, APOBEC3B expression was associated with nodal status, TNM staging and adjuvant chemotherapy of the patients with NSCLC. Further research is warranted.

No MeSH data available.


Related in: MedlinePlus

OS and DFS curves of patients with NSCLC based on their AP3B expression. (A) OS curves: all patients with low and high AP3B expression levels. (B) DFS curves: all patients with low and high AP3B expression levels.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4829547&req=5

Figure 4: OS and DFS curves of patients with NSCLC based on their AP3B expression. (A) OS curves: all patients with low and high AP3B expression levels. (B) DFS curves: all patients with low and high AP3B expression levels.

Mentions: In this study, no patients were lost to follow-up. At the end of the follow-up, 106 (48%) patients were deceased and 115 (52%) patients were still alive. The 5 year survival rates of the whole cohort is 51.6% (114/221). OS and DFS curves for the whole cohort was shown in Figure 3. Patients with high expression of AP3B demonstrated shorter OS and DFS compared with those with low expression of AP3B (OS: mean of 63.6 months versus 88.6 months, P<0.001, DFS: mean of 54.4 months versus 84.4 months, P <0.001, Fig. 4, Table 2). AP3B can also be used to differentiate prognosis of patients in T1-2 categories, N=1/2/3 categories, G1 and G2/3 grades.


Increased APOBEC3B Predicts Worse Outcomes in Lung Cancer: A Comprehensive Retrospective Study.

Yan S, He F, Gao B, Wu H, Li M, Huang L, Liang J, Wu Q, Li Y - J Cancer (2016)

OS and DFS curves of patients with NSCLC based on their AP3B expression. (A) OS curves: all patients with low and high AP3B expression levels. (B) DFS curves: all patients with low and high AP3B expression levels.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4829547&req=5

Figure 4: OS and DFS curves of patients with NSCLC based on their AP3B expression. (A) OS curves: all patients with low and high AP3B expression levels. (B) DFS curves: all patients with low and high AP3B expression levels.
Mentions: In this study, no patients were lost to follow-up. At the end of the follow-up, 106 (48%) patients were deceased and 115 (52%) patients were still alive. The 5 year survival rates of the whole cohort is 51.6% (114/221). OS and DFS curves for the whole cohort was shown in Figure 3. Patients with high expression of AP3B demonstrated shorter OS and DFS compared with those with low expression of AP3B (OS: mean of 63.6 months versus 88.6 months, P<0.001, DFS: mean of 54.4 months versus 84.4 months, P <0.001, Fig. 4, Table 2). AP3B can also be used to differentiate prognosis of patients in T1-2 categories, N=1/2/3 categories, G1 and G2/3 grades.

Bottom Line: Lung cancer ranks as the most common and lethal malignancy in America and worldwide.APOBEC3B is a newly identified DNA cytosine deaminase, which is supposed to function as a major source of DNA mutation in many different tumors.Further research is warranted.

View Article: PubMed Central - PubMed

Affiliation: 1. State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, P.R. China;; 2. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, P.R. China;

ABSTRACT
Lung cancer ranks as the most common and lethal malignancy in America and worldwide. APOBEC3B is a newly identified DNA cytosine deaminase, which is supposed to function as a major source of DNA mutation in many different tumors. In this study, we combine the data of online databases and two hundred and twenty-one primary non-small-cell lung carcinoma (NSCLC) specimens from Sun Yat-sen University Cancer Center to investigate, for the first time, the clinical role of APOBEC3B in lung cancer. We found that the APOBEC3 expression was commonly elevated in NSCLC tissues and overexpression of APOBEC3B was correlated with unfavorable prognosis of the patients with NSCLC. Furthermore, APOBEC3B expression was associated with nodal status, TNM staging and adjuvant chemotherapy of the patients with NSCLC. Further research is warranted.

No MeSH data available.


Related in: MedlinePlus